Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer

Patients with estrogen receptor-positive (ER+), HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared with a standard combination approach. These findings, from the phase 3 evERA Breast…

Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Thursday 1 October →